22UA Stock Overview
A biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioNTech SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$107.60 |
| 52 Week High | US$117.20 |
| 52 Week Low | US$69.70 |
| Beta | 0.26 |
| 11 Month Change | 6.53% |
| 3 Month Change | 35.09% |
| 1 Year Change | 16.96% |
| 33 Year Change | -64.49% |
| 5 Year Change | 422.33% |
| Change since IPO | 811.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 22UA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.7% | -0.7% | -0.02% |
| 1Y | 17.0% | -17.2% | 8.2% |
Return vs Industry: 22UA exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 22UA exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| 22UA volatility | |
|---|---|
| 22UA Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 22UA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 22UA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 6,133 | Ugur Sahin | www.biontech.de |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.
BioNTech SE Fundamentals Summary
| 22UA fundamental statistics | |
|---|---|
| Market cap | €26.05b |
| Earnings (TTM) | -€466.90m |
| Revenue (TTM) | €3.04b |
8.6x
P/S Ratio-55.8x
P/E RatioIs 22UA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 22UA income statement (TTM) | |
|---|---|
| Revenue | €3.04b |
| Cost of Revenue | €476.90m |
| Gross Profit | €2.56b |
| Other Expenses | €3.03b |
| Earnings | -€466.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
May 05, 2025
| Earnings per share (EPS) | -1.95 |
| Gross Margin | 84.31% |
| Net Profit Margin | -15.36% |
| Debt/Equity Ratio | 0% |
How did 22UA perform over the long term?
See historical performance and comparison